Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's

Clinical Trial Description

To test in a single blind randomized control study the efficacy of Rituximab versus combination of pulse cyclophosphamide and azathioprine. Both group receiving 0.5 mg/kg/daily prednisolone. ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT00699985` - Psychological Symptoms in Patients With Behcet's Disease by SCL90-R	N/A
Completed	`NCT00001865` - HAT in Eye Complications of Behcet's Disease	Phase 2
Terminated	`NCT00550498` - Stem Cell Transplantation in Ocular Lesions of Behcet's Disease	Phase 1
Completed	`NCT00700297` - Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT00699985 - Psychological Symptoms in Patients With Behcet's Disease by SCL90-R

N/A

Completed

NCT00001865 - HAT in Eye Complications of Behcet's Disease

Phase 2

Terminated

NCT00550498 - Stem Cell Transplantation in Ocular Lesions of Behcet's Disease

Phase 1

Completed

NCT00700297 - Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00664599
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	April 2006
Completion date	January 2008

Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms